GRANT: LWF Doubles Down on Partnership with Aptadel Therapeutics (Barcelona, Spain)
LWF is proud to commit $680,000 to Aptadel Therapeutics to continue their ADEL-101 research. ADEL-101 is an aptamer-based drug conjugate (ApDC) a two-pronged therapeutic designed for precision targeting and tumor cell destruction.
Dr. Holly Meany: SABRE Trial - CAR-TA (B7-H3)
Dr. Holly Meany (at Children's National Hospital) presents the upcoming SABRE Trial (NCT07172958), a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcoma, neuroblastoma and Wilms tumor.
Dr. David Loeb: A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Dr. David Loeb (Children's Hospital at Montefiore) makes a repeat guest appearance to present and discuss an upcoming Phase II Clinical Trial centered around DFMO for Ewing sarcoma and Osteosarcoma.
Dr. Maggie Fader: Functional Precision Medicine Clinical Trial
Dr. Maggie Fader (at Nicklaus Children's Hospital) discusses the ongoing Functional Precision Medicine Clinical Trial for relapsed or refractory pediatric cancer patients (NCTNCT05857969). This webinar will outline this team's unique approach to personalized medicine, utilizing patient specific ex vivo Drug sensitivity Testing (DST) and genomic profiling.
LWF Grants $700,000 to Help Launch Multiple New Trials
In 2025–2026, the Little Warrior Foundation (LWF) is proud to announce a $700,000 grant to the Beat Childhood Cancer Foundation to support the launch of three new clinical trials, including two focused on DFMO with the Beat Childhood Cancer Research Consortium (BCCRC.)
Little Warrior Issues $100,000 Emergency Grant to Continue Precision Medicine Program
When we heard Dr. Maggie Fader’s precision medicine trial for kids with relapsed cancer was about to shut down due to NIH cuts, we called an emergency board meeting—and issued a $100,000 grant to keep it alive. This trial isn’t theoretical. It’s helping kids like Sasha, who was out of options, see real results right now. Hope doesn’t wait. And neither do we.
Little Warrior Commits $150,000 to MSK to Develop Fusion-Derived Cellular Immunotherapies
Little Warrior Foundation has awarded a $150,000, two-year grant to Dr. Swati Jain at Memorial Sloan Kettering Cancer Center (MSK). This project explores a cutting-edge concept in cancer treatment: the use of fusion-derived neoantigens as targets for immunotherapy.
Ewing's U: Dr. Christine Heske: New NCI Phase I PEN-866 Clinical Trial
Dr. Christine Heske (at NCI) discusses the recently opened PEN-866 (or VTPEN) clinical trial for relapsed and refractory AYA with Ewing or Rhabdomyosarcoma (NCT04890093). We'll discuss the preclinical science behind this trial, key distinguishing features of the newly opened trial, and how patient advocacy and persistence made this trial a reality.
Ewing’s U: Dr. Bernadette Brennan: New INTER-EWING-1 Trial (UK / Europe)
Join us as we head to the other side of the pond, with trial lead Dr. Bernadette Brennan (Royal Manchester Children’s Hospital), to take look at a multi-arm and new clinical trial called INTER-EWING-1 (https://www.bcrt.org.uk/information/clinical-trials/recruiting-clinical-trials/inter-ewing-1).
Advancing ctDNA Testing for Ewing Sarcoma: A New Grant to DFCI
Little Warrior Foundation has awarded a $100,000 grant to Dr. Brian Crompton’s lab at Dana-Farber to develop a CLIA-certified liquid biopsy test for pediatric cancers. This breakthrough assay could transform diagnosis and treatment for Ewing sarcoma by enabling real-time, personalized care based on ctDNA levels.
Ewing's U: Dr. Rashmi Chugh: Phase 1 INBRX-109 Trial
Dr. Rashmi Chugh (University of Michigan) presents a phase I trial for Ewing sarcoma, centered around a new targeted agent called INBRX-109. INBRX-109 is a recombinant humanized tetravalent antibody targeting human death receptor 5 (DR5). This targeted agent will be given in combination with Irinotecan and Temozolomide.
Ewing’s U: Dr. Matteo Trucco: New METTSEO Clinical Trial for Metastatic Ewing Sarcoma
Dr. Matteo Trucco (Cleveland Clinic) discusses a new upfront trial for Metastatic Ewing sarcoma. METTSEO (Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes) will test the ability to administer frequently changing chemotherapy regimens, based on evolutionary biology principles called sequential second strikes, to patients with widely metastatic Ewing sarcoma in order to stop development of resistance to chemotherapy and improve cure rates.
GRANT: Aptadel Therapeutics (España) - $500,000
We are proud to announce our first international grant: a $500,000 commitment to Aptadel Therapeutics, based in Spain. This funding will support critical preclinical testing of an innovative new therapy, ADEL-101, that specifically targets the core genetic fusion fueling Ewing sarcoma.
Ewing’s U: New PEEL-224 Phase I/II Clinical Trial
Dr. David Shulman (Dana Farber Cancer Institute) discusses the newly opened PEEL-224 Phase I/II Clinic Trial (NCT06709495) for relapse or refractory sarcomas in AYAs. PEEL-224 is newly formulated Topoisomerase I Inhibitor with preclinical efficacy as a single agent. For this clinical trial, PEEL-224 will combined with Vincristine and Temozolomide (V, P, T).
SupraVax: Cleveland Clinic Ewing Sarcoma Vaccine Trial Update
Little Warrior Foundation has an update about the Personalized Vaccine Trial led by Dr. Pete Anderson and Dr. Timothy Chan and Cleveland Clinic known as the The SupraVax Trial.
Funding Philosophy: Valley of Death
At Little Warrior Foundation, we think about the entire path to the patient. That’s why we’re making bigger investments, like the $350,000 we granted this year or the $2.5 million we’ve committed to the upcoming vaccine trial. Translational medicine takes time — frustratingly so —but we have faith that these are necessary steps to avoid the Valley of Death.
Ewing’s U: Liquid Biopsy ctDNA detection in Ewing sarcoma
Dr. Brian Crompton (at Dana Farber Cancer Institute) discusses the ongoing research behind liquid biopsy detection of Ewing sarcoma cells and ongoing efforts to leverage this technology to risk stratify patients at diagnosis, with the ultimate aim of changing the trajectory of cancer treatment on individual basis.
Ewing's U: NK Cell Therapy for Ewing sarcoma
Join us for this special "trifecta" presentation and discussion on NK cell therapy in pediatric sarcomas. Dr. Dean Lee (Nationwide Children's Hospital) will provide an overview of NK cell therapy, Dr. Bhuvana Setty (Nationwide Children's Hospital) will provide an update on the ongoing TiNKs trial (NCT05634369), and Dr. Wen Luo (New York Medical College) will provide a preview into promising research centered around next generation NK cell therapies (CAR-NK, etc.) for Ewing sarcoma.
Ewing’s U: Dr. Chandrika Behura NEW Clinical Trial | Ck2 Inhibitor for Solid Tumors
In this episode of Ewing’s U, Dr. Chandrika Behura (at Penn State Health Children's Hospital) discusses the research behind a new CK2 inhibitor for solid tumors (including Ewing sarcoma) and shares details about a new clinical trial (BCC021) through the Beat Childhood Cancer Research Consortium.
Ewing’s U: Dr. Matthew Ladra: Proton Radiation Therapy for Pediatric Sarcomas
In this webinar, we'll hear from pediatric radiation oncologist Dr. Matthew Ladra of Children’s National Medical Center (affiliated with Johns Hopkins Sidney Kimmel Cancer Center) on proton radiation and discuss when and how proton radiation therapy might be the best option for local control in Pediatric Sarcomas, with a focus on metastatic disease.